miRBase entry: hsa-mir-625
Hsa-mir-625 is a microRNA that has been found to be down-regulated in various conditions, including Alzheimer's disease (AD) [PMC3205057]. It is one of the microRNAs predicted to …
MIR625 RNA Gene - GeneCards
2024年12月25日 · MIR625 (MicroRNA 625) is an RNA Gene, and is affiliated with the miRNA class. Diseases associated with MIR625 include Pleural Cancer and Pleural Disease. ...
Hsa-miR-625 Upregulation Promotes Apoptosis in Acute Myeloid …
The overexpression of miR-625 could decrease tumorgenesis of acute myeloid leukemia cell lines through Integrin-linked kinase signaling pathway and reducing the associated oncogenes. The …
【求助】这几组microrna有什么区别？ - 丁香通研选
2015年8月20日 · hsa-miR-625 和hsa-miR-62undefined 这2个第一个你应该清楚吧，hsa-miR-62undefined表示和前面那个互补的miRNA，于是就用了一个号标记。 hsa-mir-532-5p 和hsa …
The enhancer activity of long interspersed nuclear element derived ...
Hsa-miRNA-625 is well known as a cancer-related miRNA, oncomiR 24–28 and hsa-miRNA-625 is derived from LINEs. hsa-miRNA-625 downregulates the target genes related to several …
Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute …
In many studies, miR-625-5p has been shown to inhibit downstream pathways from affecting the metastasis and invasion of the integrin-linked kinase (ILK) signaling pathway. It has been …
这几组microrna有什么区别？ - 答魔科研
hsa-miR-625 和hsa-miR-625* 这2个第一个你应该清楚吧，hsa-miR-625*表示和前面那个互补的miRNA，于是就用了一个*号标记。 hsa-mir-532-5p 和hsa-miR-532-3p 其实和上面也没有太 …
Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute …
Acute myeloid leukemia (AML) is characterized by abnormalities of differentiation and growth of primary hematopoietic stem cells (HSCs) in the blood and bone marrow. In many studies, miR …
hsa_circ_0005692 吸附 miR-625-5p 调节 CXXC4 的表达而抑制胃癌 …
过表达 hsa_circ_0005692 或沉默 miR-625-5p 可抑制胃癌细胞的增殖、迁移和侵袭能力,并促进其凋亡,迁移侵袭相关因子 N-cadherin 和 MMP9 表达下降,而过表达 miR-625-5p 或沉默 CXXC4 …
Comprehensive Analysis to Identify LINC00511–hsa‐miR‐625…
2023年7月3日 · The LINC00511–hsa-miR-625-5p–SEMA6A axis provided new insights into the molecular mechanisms of SKCM progression, emerging as an effective therapeutic target and …